Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 known ✓ | P29474 | 2/20 | 0.32 |
| ▸ | NOS1 known ✓ | P29475 | 2/20 | 0.32 |
| ▸ | NOS2 known ✓ | P35228 | 2/20 | 0.32 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.31 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | APAF1 | O14727 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL14322290 | 0.90 | OPRK1 (0.33) | NOS3NOS1NOS2KMT2AKDM4E | |
| Acetic Acid SCHEMBL29156192 | 0.80 | P2RY6 (0.36) | OPRD1KMT2AKDM4EMEN1 | |
| Acetic Acid SCHEMBL28995037 | 0.78 | ANPEP (0.40) | KMT2AOPRK1MEN1SIGMAR1 | |
| Acetic Acid SCHEMBL27982197 | 0.77 | ANPEP (0.46) | KMT2AOPRK1MEN1SIGMAR1 | |
| SCHEMBL7061211 | 0.74 | CHRM2 (0.40) | KDM4E | |
| Acetic Acid SCHEMBL29156189 | 0.73 | TSHR (0.38) | KMT2AKDM4EOPRK1MEN1 | |
| Acetic Acid SCHEMBL8076703 | 0.73 | MIF (0.39) | KMT2AOPRK1APAF1MEN1SIGMAR1 | |
| SCHEMBL28134518 | 0.70 | SIGMAR1 (0.47) | KMT2AOPRK1MEN1SIGMAR1 | |
| Benzyl Isothiocyanate SCHEMBL28996243 | 0.69 | MIF (0.49) | SIGMAR1 | |
| Acetic Acid SCHEMBL14322291 | 0.67 | APAF1 (0.39) | KMT2AOPRK1APAF1MEN1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118355029-A | Methods of treating diffuse large B-cell lymphomas using anti-CD 79B immunoconjugates | 基因泰克公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118271445-A | Antibodies that bind to CD3 | 豪夫迈·罗氏有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-113621062-B | Antibodies that bind to CD3 | 豪夫迈·罗氏有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-110998329-B | Method for qualitatively and/or quantitatively analyzing characteristics of activatable antibodies and use thereof | 西托姆克斯治疗公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-112513085-B | PSMA binding agents and uses thereof | 詹森生物科技公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-118201637-A | Methods of treating Tau pathology | 基因泰克公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-118184781-A | Anti-CD 3 binding domains and antibodies comprising them and methods of their production and use | 阿迪马布有限责任公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-118165076-A | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof | 西托姆克斯治疗公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-118176018-A | Anti-ACVR 2A antibodies and uses thereof | 来凯医药科技(上海)有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-112812183-B | Anti-IL-36R antibodies | 勃林格殷格翰国际有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20180339041-A1 | ANTI HUMAN Gas6 MONOCLONAL ANTIBODY | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2018-11-29 | — | — | US | disclosed |
| US-10100120-B2 | Antibody which specifically binds to human CRTH2 | KYOWA HAKKO KIRIN CO., LTD (JP) | 2018-10-16 | — | — | US | disclosed |
| US-20180222994-A1 | ANTIBODY WHICH SPECIFICALLY BINDS TO HUMAN CRTH2 | KYOWA HAKKO KIRIN CO., LTD (JP) | 2018-08-09 | — | — | US | disclosed |
| EP-3323832-A1 | ANTIBODY WHICH SPECIFICALLY BINDS TO HUMAN CRTH2 | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
| US-9938349-B2 | Antibody which specifically binds to human CRTH2 | KYOWA HAKKO KIRIN CO., LTD (JP) | 2018-04-10 | — | — | US | disclosed |
| EP-3211080-A1 | ANTI HUMAN Gas6 MONOCLONAL ANTIBODY | Kyowa Hakko Kirin Co., Ltd. (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-20170121415-A1 | ANTIBODY WHICH SPECIFICALLY BINDS TO HUMAN CRTH2 | KYOWA HAKKO KIRIN CO., LTD (JP) | 2017-05-04 | — | — | US | disclosed |
| EP-1047457-A2 | USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE | MCA Development B.V. (NL) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999036105-A9 | USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE | MCA DEV B V (NL) | 1999-10-21 | — | — | WO | disclosed |
| WO-1999036105-A2 | USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE | MCA DEVELOPMENT B.V. (NL) | 1999-07-22 | — | — | WO | disclosed |